Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Victoria

$50,000.00

Facilitation ultRahigh dOse-rate aNd spaTIally-fractionatEd Radiotherapy (FRONTIER)

EF 2021-22

Résumé
Each year about 80,000 Canadians succumb to cancer, the leading cause of death in our country corresponding to 30% of deaths. Radiation therapy, along with surgery and chemotherapy, is one of the three most common treatment options, but unfortunately its efficacy is limited by radiation side effects. Two novel RT techniques - ultrahigh dose-rate (FLASH) and spatially-fractionated radiotherapy (SFRT) have recently shown great promise in improving outcomes of radiotherapy in a laboratory setting. FLASH radiotherapy consists of treatment dose delivery in sub-second intervals that are much shorter than the typical minute-long treatments. SFRT, on the other hand, is delivered with a set of small beams rather than with a uniform beam used in conventional radiotherapy. By means of FLASH and SFRT small animal studies performed on specialized equipment, reductions in radiotherapy side effects have been demonstrated for both treatment modalities. For example, mouse brains irradiated with FLASH experienced almost no cognitive function deterioration unlike mouse brains irradiated conventionally. SFRT performed on a rat model of glioblastoma multiforme, an aggressive form of brain cancer, resulted in a significantly increased mean survival from 34 days after conventional radiotherapy to 170 days. These two novel radiotherapy techniques, especially FLASH, are undoubtedly on the forefront of all current radiotherapy research and their translation to clinical use is tantalizing. Unfortunately, many obstacles must be overcome before these two radiotherapy modalities can be translated to the clinic for cancer patients' benefit. The overarching goal of this proposal is to accelerate the clinical translation of FLASH and SFRT by means of 1) building three FLASH and/or SFRT systems to enable widespread preclinical testing of these two treatment modalities, 2) providing accurate dose calculation methods for an objective interinstitutional comparison of FLASH and SFRT treatment outcomes and 3) developing equipment for real-time FLASH and SFRT dosimetry. Upon a successful completion of the proposed research, we will have provided the radiation oncology community with a number of necessary tools for widespread preclinical testing and clinical translation of FLASH and SFRT.
Programme
Discovery Grants Program - Individual
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2021-03516
Name nom
Bazalova, Magdalena
Department département
Physics and Astronomy
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2021
Award amount
50000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1505
Committee name en
Physics
Committee name fr
Physique
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
3114
Research subject group en
Physics
Research subject group fr
Physique
Research subject en
Biological and Medical Physics
Research subject fr
Physique biologique et médicale
Installment
inst:1
Partie
1
Nb partie
5
Application title
Facilitation ultRahigh dOse-rate aNd spaTIally-fractionatEd Radiotherapy (FRONTIER)
Keyword
NSERC
Application summary
Each year about 80,000 Canadians succumb to cancer, the leading cause of death in our country corresponding to 30% of deaths. Radiation therapy, along with surgery and chemotherapy, is one of the three most common treatment options, but unfortunately its efficacy is limited by radiation side effects. Two novel RT techniques - ultrahigh dose-rate (FLASH) and spatially-fractionated radiotherapy (SFRT) have recently shown great promise in improving outcomes of radiotherapy in a laboratory setting. FLASH radiotherapy consists of treatment dose delivery in sub-second intervals that are much shorter than the typical minute-long treatments. SFRT, on the other hand, is delivered with a set of small beams rather than with a uniform beam used in conventional radiotherapy. By means of FLASH and SFRT small animal studies performed on specialized equipment, reductions in radiotherapy side effects have been demonstrated for both treatment modalities. For example, mouse brains irradiated with FLASH experienced almost no cognitive function deterioration unlike mouse brains irradiated conventionally. SFRT performed on a rat model of glioblastoma multiforme, an aggressive form of brain cancer, resulted in a significantly increased mean survival from 34 days after conventional radiotherapy to 170 days. These two novel radiotherapy techniques, especially FLASH, are undoubtedly on the forefront of all current radiotherapy research and their translation to clinical use is tantalizing. Unfortunately, many obstacles must be overcome before these two radiotherapy modalities can be translated to the clinic for cancer patients' benefit. The overarching goal of this proposal is to accelerate the clinical translation of FLASH and SFRT by means of 1) building three FLASH and/or SFRT systems to enable widespread preclinical testing of these two treatment modalities, 2) providing accurate dose calculation methods for an objective interinstitutional comparison of FLASH and SFRT treatment outcomes and 3) developing equipment for real-time FLASH and SFRT dosimetry. Upon a successful completion of the proposed research, we will have provided the radiation oncology community with a number of necessary tools for widespread preclinical testing and clinical translation of FLASH and SFRT.